tbuckley/cabot-search huggingface dataset:
New features of rubella in Spain: the evidence of an outbreak
Authors: C Lemos, R Ramirez, M Ordobas, D H Guibert, J C Sanz, L Garcia, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

In most of western Europe the rubella vaccine coverage is high. However, prior to the introduction of the vaccine in Latin America, rubella susceptibility in women of childbearing age was 10-25%. Forty one (93%) countries in Latin America have adopted the rubella vaccine since 2002. The adult immigrant population in Spain constitutes a group of susceptibles. In February 2003, the Madrid Community Measles Elimination Plan detected an increase in rubella notifications in women who had been born in Latin America. A descriptive study was undertaken to characterise the outbreak. A confirmed case was a person with fever or rash and a positive IgM serology, and living in Madrid, between 1 December 2002 and 31 March 2003. The secondary attack rate (SAR) per household was calculated. A total of 19 cases of rubella were identified, 15 were confirmed and 4 were probable cases. Fourteen (73.7%) cases were women at childbearing age. The mean age was 25.1 years. One pregnancy was diagnosed with a voluntary termination. Eleven (57.9%) cases were from Ecuador. The mean time of residence in Spain was 41 months. None of the cases or the 54 (78.3%) household contacts had been vaccinated against rubella. The SAR was 9.1%. This study showed the spread of rubella in the susceptible Latin American Community that is resident in Madrid. The interventions proposed were a vaccination programme towards immigrants, a health education campaign to prevent congenital rubella, and a health professional training programme case management.
Hospitalizaciones en el norte de Portugal debidas a gripe y neumonía adquiridas en la comunidad, 2000-2005
Authors: J Dias, A M Correia, Laurinda Queirós
Journal: Eurosurveillance (2007)

Los ingresos hospitalarios por neumonia, una de las complicaciones mas habituales de la gripe, son mas frecuentes en ninos y ancianos asi como en personas que padecen enfermedades cronicas.
Les perspectives d'un Centre européen de prévention et de contrôle des maladies
Authors: M Kokki, R Haigh
Journal: Eurosurveillance (2004)

Le 30 mars 2004, le Conseil a finalement donne son aval au Reglement instaurant un nouveau Centre europeen de prevention et de controle des maladies. Il n'aura fallu que huit mois de negociations depuis la proposition de la Commission en juillet 2003.
Vigilancia de la criptosporidiosis y brotes epidémicos de transmisión hídrica en Europa
Authors: J C Semenza, G Nichols
Journal: Eurosurveillance (2007)

Cryptosporidium causa una enfermedad diarreica que puede ser particularmente grave en personas inmunodeprimidas. La criptosporidiosis es una enfermedad de declaracion obligatoria en la Union Europea, y los datos de vigilancia se recaban a traves de la European Basic Surveillance Network.
Riepilogo delle infezioni da HIV contratte in ambiente lavorativo descritte nei rapporti pubblicati entro il Dicembre 1997
Authors: B G Evans, D Abiteboul
Journal: Eurosurveillance (1999)

A partire dal 1984, quando venne documentato il primo caso di sieroconversione conseguente ad esposizione professionale a HIV (1), molti paesi industrializzati hanno introdotto dei sistemi di sorveglianza, nazionali o regionali, per l'infezione da HIV acquisita sul lavoro. Nel 1992 (2), nel 1993 (3), nel 1995 (4) e, piu recentemente, nel 1997 (5), sulla base dei rapporti gia pubblicati, sono stati redatti una serie di riepiloghi sulle infezioni contratte professionalmente. Il valore reale dell'incidenza dell'infezione da HIV contratta professionalmente e sconosciuto e probabilmente e maggiore del numero totale di casi riportati. Questo e valido anche per i paesi industrializzati che producono i resoconti disponibili. L'incidenza globale molto maggiore rispetto ai dati disponibili, dal momento che dalle aree con alta prevalenza, dove i sistemi di sorveglianza non sono ben sviluppati, giungono poche segnalazioni di esposizioni occupazionali.
Imatinib in combination with everolimus in patients with progressive advanced chordoma: results form an Italian phase 2 clinical trial
Authors: S. Stacchiotti, C. Morosi, A. Casale, E. Palassini, A.M. Frezza, A. Messina, A. Gronchi, G. Garrone, E. Venturelli, S. Pilotti, E. Tamborini, P.G. Casali
Journal: Annals of Oncology (2017)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Authors: Rodrigo Romero, Volkan I Sayin, Shawn M Davidson, Matthew R Bauer, Simranjit X Singh, Sarah E LeBoeuf, Triantafyllia R Karakousi, Donald C Ellis, Arjun Bhutkar, Francisco J Sánchez-Rivera, Lakshmipriya Subbaraj, Britney Martinez, Roderick T Bronson, Justin R Prigge, Edward E Schmidt, Craig J Thomas, Chandra Goparaju, Angela Davies, Igor Dolgalev, Adriana Heguy, Viola Allaj, John T Poirier, Andre L Moreira, Charles M Rudin, Harvey I Pass, Matthew G Vander Heiden, Tyler Jacks, Thales Papagiannakopoulos
Journal: Nature Medicine (2017)
Abstract 14661: Early Predictive Markers of Right Ventricular - Pulmonary Vascular Dysfunction in Preterm Infants With Bronchopulmonary Dysplasia
Authors: Meghna D Patel, Philip T Levy, Brittney Dioneda, Timothy J Sekarski, Mark R Holland, Aaron Hamvas, Gautam K Singh
Journal: Circulation (2015)

Introduction: Improved survival of extremely preterm infants has led to an increased recognition of bronchopulmonary dysplasia (BPD) associated with abnormal cardio-pulmonary hemodynamics. Reliable non-invasive quantitative markers for early recognition of BPD in preterm infants are lacking. The aim of this study was to evaluate quantitative echocardiographic measures of right ventricular hemodynamics (RV) as early predictive markers in infants at risk for development of BPD. Methods: A prospective study was conducted in 115 preterm infants (&lt; 29 weeks gestational age) enrolled through the Prematurity and Respiratory Outcomes Program (NCT01435187). Echocardiographic measures of RV function and pulmonary hemodynamics were evaluated at 32 and 36 weeks post-menstrual age (PMA). RV systolic function was assessed with fractional area of change (FAC), tricuspid annular plane systolic excursion (TAPSE), and global and free wall longitudinal strain. RV morphometrics were assessed with RV dimensions and areas. Pulmonary hemodynamics were assessed by pulmonary artery acceleration time (PAAT). Commonly used qualitative measures (tricuspid regurgitation velocity and septal flattening) were evaluated for comparison. BPD was classified by the NIH workshop definition. Results: RV global and free wall strain, FAC, TAPSE, and PAAT were significantly reduced, and RV morphometrics were significantly larger at 32 and 36 weeks PMA in preterm infants who developed BPD (Table 1). Qualitative measures were present in &lt; 20% of patients, and only septal flattening was significant at 32 weeks PMA in the BPD group. Conclusions: Quantitative echocardiographic measures of RV function and pulmonary hemodynamics are reliable early predictive markers of subsequent development of BPD in preterm infants. These measures are superior to commonly used qualitative measures and can be useful tools for early identification of preterm infants at high risk for BPD.
Inspección de la carne para Trichinella (cerdo, carne de caballo y de caza) en la UE : las técnicas disponibles y su implementación actual
Authors: P Webster, C Maddox-Hyttel, K Nöckler, A Malakauskas, J van der Giessen, E Pozio, P Boireau, C M O Kapel
Journal: Eurosurveillance (2006)

Una nueva directiva de la UE sobre la busqueda de Trichinella en la carne, que deberia aplicarse en 2006, impone modificaciones importantes respecto a las leyes actuales. Hay varios aspectos que requieren una atencion especial. Se recomienda una optimizacion de los metodos, particularmente en terminos de sensibilidad y de digestibilidad de la carne, asi como una simplificacion de la legislacion sobre el numero de tecnicas aceptadas, para garantizar que todos los Estados miembros de la UE disponen del mismo nivel tecnico para investigar la carne de consumo. Ademas, se necesitan recomendaciones y protocolos para optimizar los procedimientos de analisis. Este articulo presenta un punto de vista global de los metodos utilizados actualmente para buscar Trichinella en la carne, de su implementacion en la UE, y describe las ventajas e inconvenientes de cada metodo descrito, anadiendose algunas sugerencias para mejorar puntos especificos.
Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice†
Authors: Sarah Raevens, Anja Geerts, Annelies Paridaens, Sander Lefere, Xavier Verhelst, Anne Hoorens, Jo Van Dorpe, Tania Maes, Ken R. Bracke, Christophe Casteleyn, Bart Jonckx, Thomas Horvatits, Valentin Fuhrmann, Hans Van Vlierberghe, Christophe Van Steenkiste, Lindsey Devisscher, Isabelle Colle
Journal: Hepatology (2017)

Hepatopulmonary syndrome (HPS) is a severe complication of cirrhosis with increased risk of mortality. Pulmonary microvascular alterations are key features of HPS; but underlying mechanisms are incompletely understood, and studies on HPS are limited to rats. Placental growth factor (PlGF), a proangiogenic molecule that is selectively involved in pathological angiogenesis, may play an important role in HPS development; however, its role has never been investigated. In this study, we validated an HPS model by common bile duct ligation (CBDL) in mice, investigated the kinetic changes in pulmonary angiogenesis and inflammation during HPS development, and provide evidence for a novel therapeutic strategy by targeting pathological angiogenesis. Mice with CBDL developed hypoxemia and intrapulmonary shunting on a background of liver fibrosis. Pulmonary alterations included increased levels of proangiogenic and inflammatory markers, which was confirmed in serum of human HPS patients. Increased PlGF production in HPS mice originated from alveolar type II cells and lung macrophages, as demonstrated by immunofluorescent staining. Dysfunctional vessel formation in CBDL mice was visualized by microscopy on vascular corrosion casts. Both prophylactic and therapeutic anti‐PlGF (αPlGF) antibody treatment impeded HPS development, as demonstrated by significantly less intrapulmonary shunting and improved gas exchange. αPlGF treatment decreased endothelial cell dysfunction in vivo and in vitro and was accompanied by reduced pulmonary inflammation. Importantly, αPlGF therapy did not affect liver alterations, supporting αPlGF's ability to directly target the pulmonary compartment. Conclusion : CBDL in mice induces HPS, which is mediated by PlGF production; αPlGF treatment improves experimental HPS by counteracting pulmonary angiogenesis and might be an attractive therapeutic strategy for human HPS. (H epatology 2017)
GW28-e1099 Three-dimensional Reconstruction of Renal Sympathetic Nerve: Anatomy and Neural Remodeling Assessment in Hypertensive Canine Model and Patient
Authors: Bo Xiong, Jianbo Li, Peng Zhang, Yuanqing Yao, Jun Qian, Rong Jiang, Jing Huang
Journal: Journal of the American College of Cardiology (2017)
Improving treatment decisions in colon cancer: The tumor-stroma ratio (TSR) additional to the TNM classification
Authors: W. Mesker, G. van Pelt, A. Huijbers, J. van der Laak, E. Dequeker, J-F. Fléjou, R. Al Dieri, D. Kerr, J. Van Krieken, R. Tollenaar
Journal: Annals of Oncology (2017)
Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
Authors: A.J. Olszanski, R. Gonzalez, P. Corrie, A.C. Pavlick, M. Middleton, P. Lorigan, R. Plummer, S. Skaria, C. Herbert, M. Gore, S. Agarwala, A. Daud, S. Zhang, B. Bahamon, L. Rangachari, E. Hoberman, M. Kneissl, D. Rasco
Journal: Annals of Oncology (2017)
HMGA1 is a new biomarker of liposarcoma progression
Authors: R. Loria, V. Laquintana, G. Bon, D. Trisciuoglio, R. Covello, C.A. Amoreo, V. Ferraresi, C. Zoccali, M. D'Incalci, R. Biagini, R. Falcioni
Journal: Annals of Oncology (2017)
Abstract 361: Creg1 Interacts With Sec8 to Promote Cell-cell Adhesion During Cardiomyogenesis
Authors: Jie Liu, Yanmei Qi, Shu-Chan Hsu, Siavash Saadat, Saum Rahimi, Leonard Lee, Chenghui Yan, Xiaoxiang Tian, Yaling Han, Shaohua Li
Journal: Circulation Research (2016)

Cellular repressor of E1A-stimulated genes 1 (CREG1) is a 24 kD glycoprotein essential for early embryonic development. Our immunofluorescence studies revealed that CREG1 is highly expressed at myocyte junctions in both embryonic and adult hearts. To explore it role in cardiomyogenesis, we employed gain- and loss-of-function analyses demonstrating that CREG1 is required for the differentiation of mouse embryonic stem (ES) cell into cohesive myocardium-like structures. Chimeric cultures of wild-type and CREG1 knockout ES cells expressing cardiac-specific reporters showed that the cardiomyogenic effect of CREG1 is cell autonomous. Furthermore, we identified a novel interaction between CREG1 and Sec8 of the exocyst complex, which tethers vesicles to the plasma membrane. Mutations of the amino acid residues D141 and P142 to alanine in CREG1 abolished its binding to Sec8. To address the role of the CREG1-Sec8 interaction in cardiomyogenesis, we rescued CREG1 knockout ES cells with wild-type and Sec8-binding mutant CREG1 and showed that CREG1 binding to Sec8 promotes cardiomyocyte differentiation and cohesion. Mechanistically, CREG1, Sec8 and N-cadherin all localize at cell-cell adhesion sites. CREG1 overexpression enhances the assembly of adherens and gap junctions. By contrast, its knockout inhibits the Sec8-N-cadherin interaction and induces their degradation. Finally, shRNA-mediated knockdown of Sec8 leads to cardiomyogenic defects similar to CREG1 knockout. These results suggest that the CREG1 binding to Sec8 enhances the assembly of intercellular junctions and promotes cardiomyogenesis.
Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
Authors: P.A. Ott, D.T. Le, J.W. Kim, P.A. Ascierto, P. Sharma, P. Bono, K. Peltola, D. Jäger, T.R.J. Evans, F. de Braud, I. Chau, J.C. Bendell, M. Tschaika, C.T. Harbison, H. Zhao, E. Calvo, Y. Janjigian
Journal: Annals of Oncology (2017)
Antimicrobial resistance in Italy: preliminary results from the AR-ISS project
Authors: D Boccia, A Pantosti, F D'Ancona, S Giannitelli, M. Monaco, S Salmaso
Journal: Eurosurveillance (2002)

Antimicrobial resistance represents a critical problem in human medicine today, from both clinical and economic points of view. In 1999, the Council of the European Union included antibiotic resistance among the public health priorities in the Community, and a resolution entitled 'A strategy against the microbial threat' was issued (1). According to this document, the establishment or strengthening of a surveillance system for the collection of reliable and comparable data on a national and international scale is one of the main interventions needed to control and prevent antibiotic resistance. Surveillance systems should also integrate data about the use and prescription of antibiotics (2).
Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging
Authors: Omran Abu Aboud, Samy L. Habib, Josephine Trott, Benjamin Stewart, Sitai Liang, Abhijit J. Chaudhari, Julie Sutcliffe, Robert H. Weiss
Journal: Cancer Research (2017)

Abstract Many cancers appear to activate intrinsic antioxidant systems as a means to counteract oxidative stress. Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growth and exhibit reprogrammed glutamine metabolism, at least in part due to the glutathione pathway, an efficient cellular buffering system that counteracts reactive oxygen species and other oxidants. We show here that ccRCC xenograft tumors under the renal capsule exhibit enhanced oxidative stress compared with adjacent normal tissue and the contralateral kidney. Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine, a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839. Furthermore, PET imaging confirmed that ccRCC tumors exhibited increased tumoral uptake of 18F-(2S,4R)4-fluoroglutamine compared with the kidney in the orthotopic mouse model. This technique can be utilized to follow changes in ccRCC metabolism in vivo. Further development of these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of PET to identify and manage patients with ccRCC who are likely to respond to glutaminase inhibitors in the clinic. Cancer Res; 77(23); 6746–58. ©2017 AACR.
Acute Esophageal Necrosis
Authors: Takahiro Matsuo, Naoki Ishii
Journal: New England Journal of Medicine (2017)

A 63-year-old woman presented to the emergency department with a 2-day history of hematemesis and black stool. Esophagogastroduodenoscopy revealed a black esophagus with ulcerated longitudinal necrosis — findings that were consistent with acute esophageal necrosis.
Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.
Authors: Guy Hickson, Ioannis Karydis, Matthew James Wheater, Arjun Takar, Iain Wilson, Neil Pearce, Christian Ottensmeier, Sanjay Gupta, Brian Stedman
Journal: Journal of Clinical Oncology (2015)

e20000 Background: Uveal melanoma (UM) is a rare cancer with bleak prognosis. 50% of patients develop distant disease, mainly in the liver (90%), a mean survival of 6 months and 1-year survival rate of 15-20%. We have used chemosaturation percutaneous hepatic perfusion (PHP) to isolate the liver blood supply and deliver very high doses of melphalan to the liver. Previously, this has been reported to improve median hepatic progression free survival in a phase III study in metastatic UM but at the cost of significant mortality. We present our results of a large single centre experience of the treatment of UM using PHP in carefully selected patients. Methods: We analysed 22 consecutive patients (pts) (8 males; median age 51) who were planned for PHP treatment over a 30 month period. All were staged with contrast enhanced MRI, CT scan and laparoscopy with histological tumour confirmation. Data were collected for adverse events (AE), rates of survival, response and time to progression. Results: 2 pts could not be treated: 1 due to anatomical distortion from tumour making liver isolation impossible, 1 due to development of IVC clot between assessment and attempted treatment. 20 pts received 34 treatments (1-3 per pt). No procedure related deaths were seen. AE seen were grade 1 (n = 12), 2 (n = 13), 3 (n = 5) and 4 (n = 1) . The grade 4 complication was pulmonary oedema due to intraprocedural fluid overload. Coagulopathy and electrolyte disturbances were early AEs, expected following PHP. Hair loss, skin rash and myelosuppression were rare late AEs (1 patient each). 60% of pts had transient transaminitis, with 1 persistent . Radiologically 2 pts (10%) had stable disease for > 3 months, 13 (65%) a partial response in the liver with complete responses in 2 (10%). Nine deaths from disease progression occurred after a median of 264 days from the first procedure. 11 pts remain alive after a median of 280 days with one complete response ongoing at > 1 year. From the diagnosis of liver metastases 11 patients (55%) have survived to one year and 3 (15%) for > 2 years. Conclusions: Our results show that PHP can be used safely to control hepatic metastases in selected UM patients with a high rate of hepatic progression free and excellent overall survival.
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Authors: Matthias Pinter, Rakesh K. Jain
Journal: Science Translational Medicine (2017)

Renin-angiotensin system (RAS) inhibitors (RASi)-widely prescribed for the treatment of cardiovascular diseases-have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
GW28-e1160 Simultaneous therapy and median follow-up for perimembranous ventricular septal defect complicated with patent ductus arteriosus
Authors: Qiguang Wang, Xianyang Zhu, Duanzhen Zhang, Chuanju Hou, Chunsheng Cui, Po Zhang, Huoyuan Chen, Xiumin Han, Xiaotang Sheng, Lili Meng, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
GW28-e1220 Sequential Hybrid Procedure versus epicardial thoracoscopic ablation or endocardial catheter ablation procedure for long-standing persistent atrial fibrillation: Experience from a single center
Authors: Fang-Zhou Liu, Hui-Ming Guo, Yu-Mei Xue, Xian-Zhang Zhan, Hong-Tao Liao, Jian Liu, Shu-Lin Wu
Journal: Journal of the American College of Cardiology (2017)
Phase II study of ifosfamide, carboplatin and etoposide (ICE) in recurrent glioblastoma
Authors: T. Aoki, K. Nojima, T. Mizutani, M. Ishikawa, A. Takasu, N. Hashimoto
Journal: Journal of Clinical Oncology (2007)

2066 Background: To evaluate the efficacy and tolerability of ifosfamide, carboplatin and etoposide ( ICE ) in patients with recurrent glioblastoma. Methods: This was an open-label, single-center phase II trial. Forty-two patients with first recurrent glioblastoma after surgery, standard radiotherapy and a first-line temozolomide-based or ACNU-based chemotherapy, were enrolled.The primary endpoint was progression-free survival at 6 months ( PFS-6 ), and secondary endpoints were response rate, toxicity, and survival. Chemotherapy consisted of Ifosfamide ( 700 mg / m2 on day 1, 2 and 3 ), carbopaltin ( 100 mg / m2 on day 1 ), etoposide ( 70 mg / m2 on day 1, 2, and 3 ), every 6 weeks. Results: PFS-6 was 37 %. The median PFS was 17 weeks. Response rate was 27 %. Adverse events were generally mild ( grade 1 or 2 ) and consisted mainly of alopecia. Conclusions: This regimen is well tolerated and has activity in patients with recurrent glioblastoma. No significant financial relationships to disclose.
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations
Authors: Miguel Alejandro Lopez-Ramirez, Gregory Fonseca, Hussein A. Zeineddine, Romuald Girard, Thomas Moore, Angela Pham, Ying Cao, Robert Shenkar, Bart-Jan de Kreuk, Frederic Lagarrigue, Jack Lawler, Christopher K. Glass, Issam A. Awad, Mark H. Ginsberg
Journal: The Journal of Experimental Medicine (2017)

KRIT1 mutations are the most common cause of cerebral cavernous malformation (CCM). Acute Krit1 gene inactivation in mouse brain microvascular endothelial cells (BMECs) changes expression of multiple genes involved in vascular development. These changes include suppression of Thbs1, which encodes thrombospondin1 (TSP1) and has been ascribed to KLF2- and KLF4-mediated repression of Thbs1. In vitro reconstitution of TSP1 with either full-length TSP1 or 3TSR, an anti-angiogenic TSP1 fragment, suppresses heightened vascular endothelial growth factor signaling and preserves BMEC tight junctions. Furthermore, administration of 3TSR prevents the development of lesions in a mouse model of CCM1 (Krit1ECKO) as judged by histology and quantitative micro-computed tomography. Conversely, reduced TSP1 expression contributes to the pathogenesis of CCM, because inactivation of one or two copies of Thbs1 exacerbated CCM formation. Thus, loss of Krit1 function disables an angiogenic checkpoint to enable CCM formation. These results suggest that 3TSR, or other angiogenesis inhibitors, can be repurposed for TSP1 replacement therapy for CCMs.